Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Population
Cancer patients receiving vascular endothelial growth factor signaling pathway (VSP) inhibitors
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Expert panel guidance on acute VSP inhibitor hypertension offers interim direction; leaves open optimal strategies pending prospective trials.
Structured PICO
P
Population
A consensus report providing recommendations for the assessment, surveillance, and management of blood pressure in cancer patients receiving vascular endothelial growth factor signaling pathway inhibitors.
I
Intervention
Structured approach for blood pressure management including formal risk assessment, active monitoring, and a BP goal of <140/90 mmHg
O
Outcome
Safe management of blood pressure and prevention of cardiovascular complications
An expert panel recommends proactive assessment, monitoring, and management of blood pressure to a goal of <140/90 mmHg in patients receiving VSP inhibitors to prevent cardiovascular complications.
Limitations
- Limited prospectively collected data on managing acute hypertension caused by VSP inhibitors.
Cite This Study
Maitland et al. (2010) conducted a review in Cancer patients receiving Vascular Endothelial Growth Factor Signaling Pathway (VSP) Inhibitors. Vascular Endothelial Growth Factor Signaling Pathway (VSP) Inhibitors was evaluated. The NCI Cardiovascular Toxicities Panel recommends formal risk assessment, active blood pressure monitoring, and aggressive management to a goal of less than 140/90 mmHg for cancer patients receiving VSP inhibitors.